Neuroendocrine Tumors Clinical Trial
Official title:
Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors
This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with Somatostatin receptor expressing tumors who undergo imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors. 68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either at staging or during follow up.
Rationale and overall study design This study is planned to demonstrate the safety and
efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique
for diagnosis, staging, and monitoring of response to treatment in patients with
Somatostatin receptor expressing tumors who undergo imaging with a clinical indication.
Neuroendocrine tumors (NET) are rare neoplasms of neuroendocrine origin. Neuroendocrine
tumors are solid malignant tumors that arise from dispersed neuroendocrine cells found
throughout the body. They are well known for their heterogeneity which makes it difficult to
obtain uniform clinical data and establish universal guidelines for the diagnosis and
treatment of NETs. NETs are characterized by overexpression of somatostatin receptors, which
can be visualized and targeted by radiolabeled somatostatin analogues.
111In-diethylenetriaminepentaacetic acid-octreotide scintigraphy (111In-Octreotide) with
single photon emission tomography (SPECT) is currently the standard imaging modality for
evaluating patients with NETs. 111In Octreotide is the only FDA approved radiopharmaceutical
available on the market for assessing the extent of involvement by NETs at both staging and
follow up periods. However, the sensitivity of this imaging modality is lower compared to
the positron emission tomography (PET) radiotracer 68Ga-DOTA0-Tyr3]octreotide
(68Ga-DOTA-TOC). Based on the improved sensitivity, 68Ga DOTATOC PET leads to significant
changes in 30% of patients. Importantly, the radiation exposure of 68Ga-DOTATOC PET is lower
than that of 111In Octreotide and also the imaging with 68Ga-DOTATOC PET scan yields fast
read-outs on the same day compared to 24-48 hour read-outs with 111In Octreotide scan. These
advantages make the 68Ga labeled somatostatin analog more attractive from both the patient
and management perspectives. The improved resolution and quantitation of uptake obtained
with Ga-68 DOTATOC PET should provide a more accurate assessment of somatostatin receptor
density, which will lead to a more accurate prediction of treatment response to somatostatin
analogues.
While the investment costs for the scanner, the radiochemistry equipment are higher for
68Ga-DOTATOC PET/CT compared with 111In-DTPA-octreotide scintigraphy and SPECT, with the
provision of this imaging molecule by an established commercial radiopharmaceutical company
that in with compliance to FDA 21 CFR Part 212 IBA Molecular Inc, NJ, USA, this will not
pose a limitation for the Mount Sinai Medical Center. In this setting, 68Ga-DOTATOC PET/CT
production and personnel costs will be borne by the commercial entity, however, Mount Sinai
Medical Center will purchase the 68Ga-DOTATOC based on a per patient schedule. Since this
imaging modality does not have a quote for reimbursement by the insurance carriers, the
imaging cost is considered a potential burden on the patient until it is approved by the
U.S. Food and Drug Administration (FDA). There is significant amount of European based
clinical data (>1000 patients) to prove the safety and efficacy of this imaging agent,
therefore, a phase II or III clinical trial in the US is redundant and will only delay the
approval of this imaging probe. Recently, Ga-68 DOTATOC has been designated as an orphan
drug by the FDA for the management of NET. This designation will probably lead to faster
approval of the agent, which would greatly benefit NET patients in the US. Currently, there
are only several small U.S.-based clinical trials for Ga-68 labeled NET PET agents available
for patients; otherwise they must travel out of the country if the scan is required to
manage their disease.
The investigators, therefore, aim to provide this superior imaging technique to NET patients
for better disease management by the referring physicians, however, this objective cannot be
attained unless at least a partial funding mechanism exists to make it affordable by the
patients until the approval of this superior imaging probe. In this regard, the
investigators are aiming at recovering the cost of the radiotracer from the local insurance
carrier through the cost recovery system.
Participant Enrollment Participants will be recruited from the Mount Sinai Medical Center.
Participants who will be approached regarding the study are those individuals who are being
seen for known or suspected malignancies.
Patients may remain on their somatostatin therapies throughout the study with no management
change merely based on the 68Ga -DOTATOC PET/CT imaging findings. The management of these
patients will be based on the standard of care and any change will be at the discretion of
the referring physician. All pertinent dosing information must be collected and reported.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01218555 -
Study of Everolimus (RAD001) in Combination With Lenalidomide
|
Phase 1 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Withdrawn |
NCT04614766 -
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT02815969 -
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
|
||
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02174549 -
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02132468 -
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
|
Phase 2 | |
Completed |
NCT02134639 -
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
|
N/A | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Terminated |
NCT01163526 -
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
|
N/A | |
Completed |
NCT01099228 -
Combination Targeted Radiotherapy in Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00171873 -
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
|
Phase 3 | |
Active, not recruiting |
NCT05077384 -
Open-label Study of Surufatinib in Japanese Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04544098 -
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
|
Early Phase 1 | |
Active, not recruiting |
NCT02736500 -
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 |